Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

Prostate Cancer Clinical Trial

Official title:

Preliminary Investigation of Uptake in PSMA Expressing Cancer, Biodistribution and Excretion of the Novel Radio Tracer [68Ga]P16-093 by PET/CT

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03073395
• Other study ID #: 511-0003-A
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: July 21, 2017
• Est. completion date: February 28, 2023

Study information

• Verified date: January 2023
• Source: Five Eleven Pharma, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An phase I study to evaluate the uptake of [68Ga]P16-093 in known or suspected metastatic prostate or renal cancer to establish the feasibility of using [68Ga]P16-093 to image PSMA expressing cancer. Measurement of the whole body biodistribution of [68Ga]P16-093 in prostate cancer patients post primary curative-intent treatment with stable PSA to generate human radiation dosimetry data.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: February 28, 2023
• Est. primary completion date: February 28, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

DYNAMIC GROUP:

Inclusion Criteria:

1. Participants will be male = 18 years of age

2. History of histologically confirmed cancer that meets criteria for either a) or b)

1. Prostate cancer with known or suspected recurrent or metastatic disease based on clinical imaging (e.g. CT, bone scan, MRI, ultrasound, FDG PET/CT, FACBC PET/CT) within 12 months of screening. If subject is post curative-intent local treatment (e.g. radical prostatectomy, local radiotherapy, brachytherapy) they must have had no intervening change in cancer treatment.

OR

2. Renal Cell cancer with known or suspected metastatic disease based on clinical imaging (e.g. CT, bone scan, MRI, ultrasound, FDG PET/CT)

3. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria:

1. Estimated creatinine clearance (eGFR) < 30 mL/min (calculated from serum creatinine result within 30 days of screening)

2. Chemotherapy or radiation therapy within 2 weeks of screening

3. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician

4. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful completion of the study

BIODISTRIBUTION GROUP:

Inclusion Criteria:

1. Participants will be male = 18 years of age

2. History of prostate cancer that is post curative-intent local treatment (e.g. radical prostatectomy, local radiotherapy, brachytherapy) with clinical PSA levels that meet one of the following criteria

1. Post-Prostatectomy (with or without adjuvant RT): PSA level that is < 0.2 ng/mL measured over at least 2 consecutive tests OR

2. Post-Radiotherapy: PSA level that has not risen from nadir measured over at least 2 consecutive tests

3. If clinical imaging (e.g. bone scan, CT, MRI, ultrasound, PET/CT) has been done within 3 months of screening as part of standard clinical surveillance it must be negative or equivocal for sites of recurrent or metastatic disease (clinical imaging is not required for enrollment)

4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria:

1. Estimated creatinine clearance (eGFR) < 30 mL/min (calculated from serum creatinine result within 30 days of screening)

2. Androgen deprivation therapy (ADT) within 3 months prior to screening

3. Chemotherapy or radiation therapy within 2 weeks of screening

4. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician

5. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful completion of the study

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Kidney Neoplasms
• Prostate Cancer
• Renal Cancer

Intervention

Drug:
• [68Ga]P16-093
Imaging by Positron Emission Tomography after iv injection of [68Ga]P16-093

Locations

Country	Name	City	State
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Five Eleven Pharma, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Uptake of [68Ga]P16-093 in metastatic prostate and renal cancer	Standard uptake value (SUV) of [68Ga]P16-093 in apparent lesions detected by PET/CT.	0.5 - 3 hours after injection
Primary	Radiation dosimetry of [68Ga]P16-093 in patients with a history of prostate cancer	Radiation dosimetry (organ absorbed dose and effective dose) will be determined using region of interest data drawn on sequential PET/CT images and data from blood and / or urine obtained during scanning.	up to 3 hours after injection